Business Overview
Cynata Therapeutics is a clinical-stage biotechnology company developing cell therapies based on Cymerus, its induced pluripotent stem cell (iPSC)-derived mesenchymal stem cell (MSC) platform. The core proposition is manufacturing: instead of relying on variable donor tissue, Cynata generates a continuous iPSC-derived MSC supply from a single donation, aiming for scale, consistency, and cost efficiency. The company's pipeline spans immune and inflammatory indications including acute graft-versus-host disease (aGvHD), osteoarthritis (OA) and chronic wounds/diabetic foot ulcers (DFU). Cynata operates an asset-light model in Australia with global. . .
Gain full access to all our premium investment intelligence
Plans from $9.99 per week, cancel anytime.
Subscribe or upgrade to Full Stock Picks to view this content